Vivitrol is not an opioid. It is the exact opposite: a pure opioid antagonist, meaning it blocks opioid receptors rather than activating them. The active ingredient in Vivitrol is naltrexone, which binds to opioid receptors in the brain but produces no opioid effects whatsoever. It does not cause a high, does not relieve pain, and does not lead to physical or psychological dependence.
This distinction matters because Vivitrol is often mentioned alongside medications like methadone and buprenorphine, which do activate opioid receptors to varying degrees. Understanding where Vivitrol fits in that picture can help clarify what it actually does and who it’s designed for.
How Vivitrol Works
Vivitrol has the highest binding affinity for the mu opioid receptor, the same receptor that heroin, fentanyl, and prescription painkillers target. But instead of switching that receptor on, naltrexone sits on it like a lock, preventing any opioid from getting through. If you were to use an opioid while Vivitrol is active in your system, you would feel little to no effect from it because the drug is physically occupying the receptor site.
This blocking action also reduces cravings over time. Vivitrol is given as an injection of 380 mg into the muscle once every four weeks. Because it’s a long-acting shot rather than a daily pill, the medication releases steadily over the course of a month, which removes the need to make a daily decision about taking it.
Vivitrol vs. Methadone and Buprenorphine
The three FDA-approved medications for opioid use disorder work in fundamentally different ways, and this is where the opioid question gets confusing for many people. Methadone is a full opioid agonist. It activates opioid receptors completely, which is why it’s dispensed under strict supervision at specialized clinics. Buprenorphine is a partial opioid agonist, activating the same receptors but only partially, producing a ceiling effect that limits its potential for misuse.
Vivitrol occupies a completely different category. It does not activate opioid receptors at all. It blocks them. This means it produces no opioid-like effects: no euphoria, no sedation, no respiratory depression. You cannot become dependent on it. For people who want a medication-assisted approach that involves zero opioid receptor activation, Vivitrol is the only option among the three.
The Opioid-Free Requirement Before Starting
Because Vivitrol aggressively blocks opioid receptors, starting it while opioids are still in your system can trigger precipitated withdrawal, a sudden, severe version of withdrawal that can be intense enough to require hospitalization. This isn’t ordinary withdrawal that builds gradually. It hits within minutes of the injection and can be far more painful than letting withdrawal run its natural course.
To avoid this, you need to be completely opioid-free for a minimum of 7 to 10 days before your first Vivitrol injection if you were using short-acting opioids. If you’re transitioning from methadone or buprenorphine, the waiting period may need to be at least two weeks, since those medications leave the body more slowly. Providers typically confirm you’re opioid-free before administering the shot.
This waiting period is one of the biggest practical barriers to starting Vivitrol. The 7 to 14 days of withdrawal and early recovery you need to get through before your first injection can feel like an enormous hurdle, especially without the cushion that buprenorphine or methadone provides during that same window.
How Well It Works
Vivitrol’s effectiveness depends heavily on whether people stay on it. A Los Angeles County pilot program found that treatment completion rates were notably higher among people receiving Vivitrol compared to county averages: 46.6% versus 32.9% for outpatient counseling, and 64.1% versus 39.2% for residential treatment. Treatment engagement, meaning people actually showing up and participating, was also stronger in the Vivitrol group.
Craving scores in that same pilot dropped sharply after the first injection, falling from an average of 19.3 at baseline (well above the relapse danger threshold of 10) to 6.6 by week four. These numbers suggest that the receptor-blocking effect translates into a real, measurable reduction in the urge to use.
The Overdose Risk When It Wears Off
One critical safety concern with Vivitrol is what happens when the medication leaves your system. While the shot is active, it blocks the effects of opioids, which means your body’s tolerance drops significantly. If you relapse after missing a dose or stopping treatment, the amount of opioid that your body could previously handle may now be enough to cause an overdose.
There’s also evidence that Vivitrol may sensitize opioid receptors over time. Because the brain reacts to having less opioid activity while receptors are blocked, those receptors may become more responsive once the blockade lifts. This could make a relapse even more dangerous than it would be after a period of simple abstinence. The protection Vivitrol provides may also begin to decline during the final week before a scheduled monthly injection, creating a vulnerable window.
In 2019, the FDA warned the manufacturer for downplaying this overdose risk in its marketing materials. If you’re on Vivitrol, staying on schedule with monthly injections is essential, and understanding the danger of using opioids after the medication wears off could be lifesaving.
What Vivitrol Feels Like Day to Day
Because Vivitrol is not an opioid and produces no activation of opioid receptors, it doesn’t change how you feel in the way methadone or buprenorphine might. There’s no sedation, no warmth, no noticeable “medicated” sensation for most people. The primary experience is a reduction in cravings and the knowledge that using opioids won’t produce a high. Some people find this freeing. Others find the absence of any pharmacological cushion challenging, particularly in early recovery.
Common side effects include nausea, fatigue, headache, and soreness at the injection site. Injection site reactions can occasionally be more serious, including hardened lumps or tissue damage, so rotating injection sites and monitoring the area between doses is standard practice.